Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tazemetostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 known ✓ | Q15910 | 20/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | EED | O75530 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | RBBP4 | Q09028 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | SUZ12 | Q15022 | 1/20 | 1.00 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 1.00 |
| ▸ | EZH1 | Q92800 | 1/20 | 1.00 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tazemetostat SCHEMBL13276848 | 1.00 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL13277005 | 0.99 | EZH2 (0.99) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL16653521 | 0.99 | EZH2 (0.99) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL15313373 | 0.99 | EZH2 (0.99) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL29361941 | 0.99 | EZH2 (0.99) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL13276853 | 0.97 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL31087432 | 0.97 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL31087436 | 0.96 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL13277447 | 0.96 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL13276541 | 0.96 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1795 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| US-12636283-B2 | Inhibition of PRC2 subunits to treat eye disorders | FONDATION ASILE DES AVEUGLES (CH) | 2026-05-26 | — | — | US | claimed |
| WO-2026099526-A1 | COMBINATION OF INHIBITORS OF IL-1BETA, CCR5 OR CXCR2 CYTOKINE RECEPTORS FOR USE IN THE TREATMENT OF METASTASIS | FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (ES) | 2026-05-15 | — | — | WO | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| EP-4058604-B1 | COMPOSITIONS AND METHODS FOR REGULATING EGFR AMPLIFICATION IN CANCER CELLS FOR IMPROVING EGFR-TARGETED ANTI-CANCER AGENT | INSTITUTE FOR CANCER RES (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4727596-A2 | ANTIBODY-DRUG CONJUGATES AND LINKERS AND METHODS OF USE THEREOF | Ohio State Innovation Foundation (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4720133-A1 | GD2-SPECIFIC CHIMERIC ANTIGEN RECEPTOR EFFECTOR CELLS FOR USE IN THE TREATMENT OF SOLID TUMORS, POSSIBLY IN COMBINATION WITH ENHANCER OF ZESTE HOMOLOG 2 (EZH2) INHIBITORS | Ospedale Pediatrico Bambino Gesù (IT) | 2026-04-08 | — | — | EP | claimed |
| EP-4722203-A1 | 3,4-DIHYDROPHTHALAZIN-1(2H)-ONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Academy of Military Medical Sciences (CN) | 2026-04-08 | — | — | EP | claimed |
| EP-4719606-A2 | GCN2 AND PERK KINASE MODULATORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-08 | — | — | EP | claimed |
| CN-114177299-A | Antitumor pharmaceutical composition containing EZH2 inhibitor and SCD1 inhibitor and application thereof | 北京大学第三医院（北京大学第三临床医学院） | 2022-03-15 | — | — | CN | claimed |
| CN-114129565-A | Application of histone methyltransferase EZH2 inhibitor in product for promoting bone metabolism into high conversion to repair bone defect | 上海交通大学医学院附属第九人民医院 | 2022-03-04 | — | — | CN | claimed |
| WO-2022042527-A1 | SMALL-MOLECULE DRUG FOR TREATING DISEASES RELATED TO INNER EAR AND INTESTINAL EPITHELIAL TISSUE INJURIES | 北京大学 | 2022-03-03 | — | — | WO | claimed |
| CN-114085803-A | Establishment of organoid culture systems with regenerative properties | 北京大学 | 2022-02-25 | — | — | CN | claimed |
| EP-3957631-A1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| CN-108349958-B | Methods of treating MRTO/SCCOHT with EZH2 inhibitors | EPIZYME股份有限公司 | 2022-02-15 | — | — | CN | claimed |
| WO-2022026933-A2 | IN VITRO DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-02-03 | — | — | WO | claimed |
| WO-2022026932-A2 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-02-03 | — | — | WO | claimed |
| US-20220031668-A1 | METHODS OF INHIBITING PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE 2 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2022-02-03 | — | — | US | claimed |
| US-20220023293-A1 | EZH2- FGFR INHIBITION IN CANCER | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2022-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636283-B2 | Inhibition of PRC2 subunits to treat eye disorders | EZH2, EZH1, EED | EZH2 1/4885NR1I2 701/4885EED 3/4885 |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | SGMS2, SGMS1, LIPA | EZH2 2095/4885NR1I2 4643/4885EED 1264/4885 |
| US-20220031668-A1 | METHODS OF INHIBITING PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE 2 | PLOD2, TPSB2, PLOD1 | EZH2 993/4885NR1I2 2935/4885EED 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.